US FDA delays on biosimilar approvals
Rituximab BLA received a CRL; abatacept and semaglutide approvals face regulatory uncertainty.
high · management_commentary
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Revlimid revenue decline
Revlimid sales are declining faster than expected, with Q3 likely the last quarter of meaningful contribution.
high · analyst_questionSemaglutide Canada pricing and competition
Multiple filers and potential compounding pharmacy entry could lead to aggressive pricing and lower margins.
medium · analyst_questionPatent litigation outcome in India for semaglutide
Awaiting Delhi High Court decision; adverse ruling could delay India launch and impact export plans.
medium · analyst_question